July 30, 2024

6465 Systematic review of RCT to determine the efficacy and safety of Tiotropium, as add-on to inhaled corticosteroids for mild-persistent asthma in children

View Full Paper

Ask AI

Bookmark

Tiotropium as add-on therapy significantly increases peak FEV1 in children with asthma, highlighting its efficacy.
The adjusted mean difference was 164 mL for the 5 µg dose and 170 mL for the 2.5 µg dose, both statistically significant.
Systematic review of randomized controlled trials included studies from 2013 to 2023 across multiple databases, focusing on children aged 1–17 years with asthma symptoms for 12 or 48 weeks periods of treatment or observation and measuring peak FEV1 response as primary outcome measure. 12 weeks for severe asthma and 48 weeks for moderate asthma treatment showed different responses and significance levels across age groups and dosages used, with safety tolerability comparable to placebo for mild to moderate adverse effects observed.

Discussion

No takes yet. Share an insight, caveat, or question.

Systematic review shows efficacy of Tiotropium add-on therapy for mild persistent asthma in children, suggesting improved lung function.

Malik et al. (2024) studied this question.

View Full Paper

Ask AI

Bookmark